Attovia Says Phase 1b ATTO-1310 Gave 82% Of Chronic Itch Patients 4-Point Relief At Week 12 vs. 22% On Placebo; Atopic Dermatitis Itch Response 44% vs. 75% Placebo
Share
Why It Matters
Attovia's itch medicine worked really well on chronic itch patients. But it did not work as well as hoped for skin allergy itch, so results were mixed.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.